Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar

Sema Yılmaz

Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar

Öz

Aksiyel spondiloartropati, omurgayı ve sakroiliak eklemleri tutan, inflamatuar bel ağrısı ve ilerleyici omurga tutukluğuna neden olan kronik inflamatuar romatolojik bir hastalıktır. Aksiyel spondiloartropati tedavisinin amaçları; ağrı ve tutukluk gibi semptomları azaltmak, postürü korumak ve omurga füzyonunu önlemektir. Ankilozan spondilitin aksiyel tutulumunda hastalık modifiye edici anti-romatizmal ilaçların yararlı olduğuna dair kanıt bulunmamaktadır. Steroid olmayan anti inflamatuar ilaçlar ve anti-tümör nekroz faktör alfa ilaçlar, aksiyel spondiloartropati tedavisinde etkinliği olan ilaçlardır.

Anahtar Kelimeler

Aksiyel,spondiloartropati,tedavi

Kaynakça

Referans1 Zochling J, Smith EU. Seronegative spondyloarthritis. Best Pract Res Clin Rheumatol 2010;24:747-756.
Referans2 Onen F, Akar S, Birlik M, et al. Prevalence of ankylosing spondylitis and related spondyloarthritis in urban area of Izmir, Turkey. J Rheumatol 2008;35:305-309.
Referans3 Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial spondyloarthritis: a new disease entity, not necesssarily early ankylosing spondylitis. Ann Rhem Dis 2013;72:162-164.
Referans4 Robinson PC, Brown MA. The genetics of ankylosing spondylitis and axial spondyloarthritis. Rheum Dis Clin North Am 2012;38:539-553.
Referans5 Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815-822.
Referans6 Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondyloarthritis: results fromtheGerman Spondyloarthritis Inception Cohort. Arthritis Rheum 2009;60:717-727.
Referans7 Burgos-Vargas R, Braun J. Inflammatory back pain. Rheum Dis Clin North Am 2012;38:487-499.
Referans8 Weisman MH. Inflammatory back pain: the United States perspective. Rheum Dis Clin North Am 2012;38:501-512.

Referans9 Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009;68:784-788.
Referans10 Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-783.
Referans11 Braun J, van der Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
Referans12 van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-908.
Referans13 Passalent LA, Soever LJ, O’Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol 2010;37:835-841.
Referans14 Lubrano E, D’Angelo S, Parsons WJ, et al. Effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria. Rheumatology (Oxford) 2007;46:1672-1675.
Referans15 Calin R, Elswood J. A prospective nationwide cross-sectional study of NSAI usage in 1331 patients with ankylosing spondylitis. J Rheumatol 1990;17:801-803.
Referans16 Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondylarthritis: results from the German Spondylarthritis Inception Cohort 2012;71:1616-1622.
Referans17 Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006;33:722-731.
Referans18 Ward MM. Sulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication? Arthritis Rheum 2011;63:1472-1474.
Referans19 Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006;18:CD004524.
Referans20 Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Muñoz-Valle JF, Gamez-Nava JI. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004;31:1568-1574.
Referans21 Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 2014;73:243-246.
Referans22 Braun J, Bollow M, Seyrekbasan F, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 1996;23:659-664.
Referans23 Gunaydın I, Pereira PL, Daikeler T, et al. Magnetic resonance imaging guided corticosteroid injections of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol 2000;27:424-428.
Referans24 McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.
Referans25 Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-863.
Referans26 van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-929.
Referans27 Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-345.
Referans28 Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006;55:812-816.
Referans29 Haibel H, Sieper J. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? Curr Opin Rheumatol 2010;22:388-392.
Referans30 Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97.
Referans31 Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor  inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-2654.
Referans32 Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-715.
Referans33 Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60:946-954.
Referans34 Vander Cruyssen B, Munoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 2010;49:73-81.

Ayrıntılar

Birincil Dil

Türkçe

Konular

-

Bölüm

Derleme

Yazarlar

Sema Yılmaz

Yayımlanma Tarihi

24 Mart 2016

Gönderilme Tarihi

8 Kasım 2017

Kabul Tarihi

11 Kasım 2014

Yayımlandığı Sayı

Yıl 2015 Cilt: 29 Sayı: 1

IZ

https://izlik.org/JA47JW62YD

Kaynak Göster

RIS / Bibtex

APA

Yılmaz, S. (2016). Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 29(1), 57-64. https://izlik.org/JA47JW62YD

AMA

1.Yılmaz S. Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar. DEU Tıp Derg. 2016;29(1):57-64. https://izlik.org/JA47JW62YD

Chicago

Yılmaz, Sema. 2016. “Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar”. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi 29 (1): 57-64. https://izlik.org/JA47JW62YD.

EndNote

Yılmaz S (01 Mart 2016) Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi 29 1 57–64.

IEEE

[1]S. Yılmaz, “Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar”, DEU Tıp Derg, c. 29, sy 1, ss. 57–64, Mar. 2016, [çevrimiçi]. Erişim adresi: https://izlik.org/JA47JW62YD

ISNAD

Yılmaz, Sema. “Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar”. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi 29/1 (01 Mart 2016): 57-64. https://izlik.org/JA47JW62YD.

JAMA

1.Yılmaz S. Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar. DEU Tıp Derg. 2016;29:57–64.

MLA

Yılmaz, Sema. “Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar”. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, c. 29, sy 1, Mart 2016, ss. 57-64, https://izlik.org/JA47JW62YD.

Vancouver

1.Sema Yılmaz. Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar. DEU Tıp Derg [Internet]. 01 Mart 2016;29(1):57-64. Erişim adresi: https://izlik.org/JA47JW62YD